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Animal studies and preliminary clinical trials have shown that cannabidiol (CBD)-enriched
extracts may have beneficial effects for children with treatment-resistant epilepsy.
However, these compounds are not yet registered as medicines by regulatory agencies.
We describe the cases of two children with treatment-resistant epilepsy (Case A with left
frontal dysplasia and Case B with Dravet Syndrome) with initial symptom improvement
after the introduction of CBD extracts followed by seizure worsening after a short time.
The children presented typical signs of intoxication by 19-THC (inappropriate laughter,
ataxia, reduced attention, and eye redness) after using a CBD-enriched extract. The
extract was replaced by the same dose of purified CBD with no 19-THC in both
cases, which led to improvement in intoxication signs and seizure remission. These
cases support pre-clinical and preliminary clinical evidence suggesting that CBD may
be effective for some patients with epilepsy. Moreover, the cases highlight the need
for randomized clinical trials using high-quality and reliable substances to ascertain the
safety and efficacy of cannabinoids as medicines.
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INTRODUCTION
Novel antiepileptic compounds with new mechanisms of action, fewer side effects, and better safety
and tolerability profiles have been approved over the last years. However, although more than 20
different drugs approved for the treatment of epilepsy exist today, around 30% of patients continue
to have seizures (Brodie et al., 2012). Modern neurosurgery techniques are an option for these
patients, but drug-resistant epileptic patients often fail to meet the clinical criteria for surgery, and
a significant number of operated patients do not achieve full seizure remission. Together, these
obstacles have led patients with drug-resistant epilepsy (defined as the failure to achieve seizure
remission after trials with at least two adequate medications, ILAE – Blümcke et al., 2016) and
Frontiers in Pharmacology | www.frontiersin.org 1 September 2016 | Volume 7 | Article 359
fphar-07-00359 September 29, 2016 Time: 13:29 # 2
Crippa et al. THC Intoxication by CBD-Enriched Extract
their families to seek new medications, which highlights the
importance of the search for novel, effective pharmacological
options with improved tolerability and different mechanisms of
action.
The medicinal effects of cannabis in epilepsy have been known
for centuries and, nowadays, the anticonvulsant properties of
its components have received increasing attention (Leo et al.,
2016). The discovery of endocannabinoids and cannabinoid
receptors in the brain has renewed the interest in the potential
of cannabinoid compounds to treat seizures (dos Santos et al.,
2015). The Cannabis sativa plant contains more than 400
compounds, of which 100 are known as phytocannabinoids. The
two cannabinoids with the highest concentrations in cannabis are
delta9-tetrahydrocannabinol (19-THC), responsible for most of
the psychotomimetic effects of the drug, and cannabidiol (CBD),
the most common non-psychoactive cannabinoid (Crippa et al.,
2010, 2015).
Anecdotal reports suggest that cannabis has an anti-seizure
potential and could thus be used to treat subjects with epilepsy.
Cannabis is currently approved for the treatment of epilepsy
in several states of the United States and in Israel and Canada
(Paolino et al., 2016; Tzadok et al., 2016). However, the lack
of controlled studies and the fact that cannabis contains many
other substances (including other cannabinoids at different
concentrations) have hindered definitive conclusions. Moreover,
reports suggest that crude cannabis may have no efficacy and
may even exacerbate epileptic seizures (Tofighi and Lee, 2012;
Hamerle et al., 2014).
Animal studies and preliminary clinical trials have shown
significant improvements in children with treatment-resistant
epilepsy treated with CBD-enriched extracts (Rosenberg et al.,
2015). However, these compounds are not yet registered as
medicines by regulatory agencies. The general press and social
media have raised attention to these products in countries such
as the United States, United Kingdom, and Brazil. This led to the
development of a wide range of cannabis-derived products for
oral use with no regulation, quality assurance, or accurate content
labeling (Vandrey et al., 2015). Led by despair, many families have
resorted to these products (usually commercialized as dietary
supplements) in an attempt to control the seizures of their
children (Vandrey et al., 2015). The potential chronic medical
use of non-purified CBD extracts raises important concerns,
particularly in children and adolescents with a developing brain.
First, the long-term use of drugs containing THC may have
adverse and long-lasting harmful effects such as the onset of
chronic psychiatric disorders, addiction, cognitive impairment,
and changes in brain function that can have an impact on
educational, professional, and social achievements (Volkow et al.,
2014; Andrade, 2016). Second, the use of edible products makes it
difficult to titrate doses, which can lead to over- or under-dosing
and implies the risk of drug-interactions with other medicines.
Third, due to the necessary chronic use of these products and
the long half-life of 19-THC, cannabis-derived products can
cause intoxication in patients with clinical, cognitive, and motor
impairments, with detrimental consequences (Tofighi and Lee,
2012; Hamerle et al., 2014). The intoxication effects of 19-
THC include mild euphoria, ataxia, decreased attention, red
FIGURE 1 | (A,B) Axial T2-weighted TSE MRI. Coronal T2-weighted TSE MRI
(C) and axial computed tomography after surgery (D). The arrows show a
mildly hypoplastic frontal lobe with focal T2 signal hyperintensity on the
cortico-subcortical transition (A–C) and the resected region (D).
eyes, irritability (Martin-Santos et al., 2012) and, in epilepsy
patients, possible seizure worsening (Friedman and Devinsky,
2015). Here, we describe two cases of children with treatment-
resistant epilepsy in seizure remission who eventually presented
intoxication by 19-THC with the use of edible CBD-enriched
extracts and who attained full remission again after switching to
purified CBD.
CASE A
A 10-year-old girl was diagnosed with refractory epilepsy and
left frontal dysplasia at 5 months of age. Prior to cannabinoid
treatment she presented about three complex focal seizures.
Treatment with phenytoin, topiramate, carbamazepine,
levetiracetam, lamotrigine, primidone, and clobazam for
appropriate periods and at adequate doses did not lead to
seizure remission. The patient underwent focal resection of the
left anterior frontal lobe at age 8 (Figure 1) and was seizure-
free for 4 months. Her histological diagnosis after surgery
was focal cortical dysplasia type 1b. After 4 months, seizures
reappeared every day in the morning, despite treatment with
topiramate, valproate, and clobazam. She was then started
on an oral CBD-enriched extract (16% CBD, 208 mg/day or
6 mg/Kg/day; divided in three doses of 70 mg; in addition to
topiramate 1 mg/kg/day, clobazan 0.4 mg/kg/day, and valproate
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12.7 mg/kg/day), which eliminated seizures and improved
general behavior, speech, understanding, and attention. After
4 months, the child started to present inappropriate laughter,
ataxia, reduced attention, irritability, aggressiveness, spasms, and
bilateral mydriasis with eye redness (Figure 2A). An analysis
of the extract (which remained the same during the initial
treatment) detected 4.03% of 19-THC and 89.6% of CBD,
and a hair test showed the same concentrations of the two
cannabinoids. The CBD-enriched extract was then replaced
by the same dose of purified CBD (99.6%, dissolved in corn
oil−BSPG-Pharm, Sandwich, UK) with no 19-THC, which led
to complete improvement of all intoxication signs (Figure 2B)
after 1 week, as assessed by clinical evaluation and EEG results
(Figure 3), and to complete seizure remission after 4 weeks of
the new treatment.
CASE B
A 7-year-old boy had a diagnosis of refractory epilepsy due
to SCN1A mutations associated with Dravet syndrome. Prior
to treatment with cannabinoids, he presented daily complex,
focal, myoclonic, tonic, and absence seizures. In addition to
severe myoclonic epilepsy, the child also presented behavioral
and developmental delays, hyperactivity and impulsiveness,
and autistic-like behaviors. The boy underwent anticonvulsant
treatment for appropriate periods and with adequate doses,
failing to respond to several drugs including stiripentol, valproic
acid, oxcarbazepine, topiramate, levetiracetam, phenytoin,
phenobarbital, and sulthiame. The patient was then started
on an orally administered CBD-enriched extract, 16% CBD,
250 mg/day or 12.5 mg/Kg/day; divided in two doses of 125 mg;
in addition to topiramate 3.75 mg/KG/day and valproate
24 mg/kg/day), which reduced seizures (from 1–2 a day to 1 a
month) and improved general behavior, speech, understanding,
and attention. After 3 months, however, the patient started to
present ataxia, reduced attention, irritability, aggressiveness, and
seizure worsening. An analysis of the cannabis extract detected
3.1% of 19-THC and 91% of CBD, proportions that were also
confirmed through a hair test. The CBD-enriched extracts
(which remained the same during the initial treatment) was
replaced by 200 mg/day of purified CBD (divided in two doses
of 100mg, oral solution with 99.6% CBD dissolved in corn oil
(BSPG-Pharm, Sandwich, UK) and no 19-THC, which was later
increased to 300 mg/day divided in two doses of 150 mg. This
dose led to complete improvement of all intoxication symptoms
after 1 week of treatment as indicated by clinical evaluation, EEG
improvements, and complete seizure remission after 3 weeks of
the new treatment. The child also had a clear improvement in
most of the autistic-like symptoms over the course of 6 months,
including poor communication (vocabulary and spelling), poor
social interaction, and repetitive and limited behavior, which
allowed the boy to start school and get involved in sports
activities like swimming.
Follow up assessments at 1 year (Case A) and 1 year and
10 months (Case B) showed remission of seizures and clear
progressive improvement of the remaining general symptoms
FIGURE 2 | Improvement of eye redness (from A to B) after
replacement of the cannabidiol (CBD)-enriched extract.
with the use of pure CBD. The other medications remained stable
before and during the time of transition from the cannabinoid
extract to the purified CBD in both cases. Likewise, there were no
changes in the dose or frequency of administration of the purified
CBD oil. No side-effects were reported for any dose of CBD used
and plasmatic levels of the adjuvant antiepileptics did not change
during the trial in the two cases.
DISCUSSION
The present report is in line with pre-clinical and preliminary
clinical data suggesting that CBD (and perhaps 19-THC) may
be effective for some patients with epilepsy. However, the
adverse events in both children, including 19-THC intoxication
and increased seizures, highlight the need for accurate dosing
standards and quality assurance of cannabis-derived medications.
The use of edible products makes it difficult to titrate doses and
to establish the actual amount of cannabinoids across different
products or different batches of a same product. Moreover, when
taken orally, 19-THC leads to the synthesis of much larger
amounts of 11-OH-THC compared to when it is ingested through
smoking. Since 11-OH-THC is also active, it is possible that its
psychopharmacological effects may combine with those of 19-
THC to produce stronger effects in the CNS (Benjamin and
Fossler, 2016). This is of particular concern when we consider
that the pharmacological potency of 19-THC is much higher
than that of CBD, and thus the amount of 19-THC required to
produce an effect (as well as side-effects) at a given intensity is
much lower than the amount of CBD. Our patients, for instance,
who received 208 mg and 250 mg of CBD-enriched extract with
4.03% and 3.1% of 19-THC, would ingest 8.3 mg and 7.5 mg of
19-THC, which can be considered a very high dose (Benjamin
and Fossler, 2016), especially for children.
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FIGURE 3 | (A) EEG before CBD: generalized, sharp wave, regular, in burst, high voltage in the frontal areas; (B) EEG after CBD: diffuse slowing in the background.
Surveys with caregivers and patients have also examined
the effects of CBD-enriched extracts in epilepsy. One of such
surveys involving parents of children with severe epilepsies in a
Facebook group reported improvements in 16 out of 19 patients
treated with CBD/19-THC-enriched extracts, and two patients
were reported to have become seizure-free (Porter and Jacobson,
2013).
A retrospective case series of 75 children with refractory
epilepsy taking oral cannabis extracts reported that 25 (33%)
patients presented>50% reduction in seizure frequency, whereas
44% had adverse events including increased seizures (13%)
and rare events such as developmental regression, abnormal
movements, status epilepticus requiring intubation, and death
(Press et al., 2015). More recently, a retrospective study described
the successful effects of CBD-enriched medical cannabis in 74
children (1–18 years old) with refractory epilepsy from five Israeli
pediatric epilepsy clinics (Tzadok et al., 2016). CBD-enriched
treatment significantly reduced the frequency of seizures in most
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of the children (66/74, 89%) and only five (7%) patients reported
seizure exacerbation that led to the discontinuation of treatment
with CBD-enriched extracts. Despite this, minor and infrequent
side effects were reported.
There are anecdotal reports describing the antiepileptic effects
of crude cannabis (Friedman and Devinsky, 2015), but evidence
of seizure exacerbation and lack of effects is also available
(Tofighi and Lee, 2012; Hamerle et al., 2014). Since C. sativa
contains many other substances, with different cannabinoid
concentrations and ratios, there is no sufficient information
to allow for definitive conclusions (Rosenberg et al., 2015).
Moreover, the pharmacokinetic interactions of CBD and 19-
THC (and of other cannabinoids) raise safety concerns, as
both compounds can inhibit cytochrome P450 enzymes (CYP2C
and CYP3A4) that act in the metabolism of many of the
anticonvulsants commonly used with CBD (Geffrey et al.,
2015).
Some therapeutic trials have tested the effects of isolated
cannabinoids in the treatment of epilepsy. In an early prospective,
placebo-controlled three-month trial in adults with treatment-
resistant epilepsy, Mechoulam and Carlini (1978) showed that
two out of four patients treated with purified CBD (200 mg/day)
became seizure free and one presented partial improvement.
Later, a prospective, placebo-controlled trial in adolescents and
adults with treatment-resistant convulsive seizures treated for
8–18 weeks reported that four out of eight subjects in the
purified CBD (200–300 mg/day) arm became seizure free (Cunha
et al., 1980). More recently, in an open-label trial (Devinsky
et al., 2016), patients (N = 162, 1–30 years-old) with severe
childhood-onset refractory epilepsy were enrolled in an expanded
access program. Participants were given purified oral CBD
(from 2 to 5 mg/kg/day to a maximum up-titrated dose of
25 mg/kg/day) during 12 weeks. The authors reported that CBD
reduced seizure frequency and presented an adequate safety
profile.
The pharmacological mechanisms underlying the antiepileptic
action of CBD are not yet well understood, as CBD
interferes with different neurotransmitter systems in a
number of ways. For instance, there is evidence that
CBD inhibits the reuptake and metabolism of anandamide,
increases hippocampal neurogenesis, interacts with 5HT1A
and TRPV1 receptors, and presents antioxidant and
neuroprotective effects which may, at least in part, help
to explain its anticonvulsant profile (Reif et al., 2007;
Zuardi, 2008; Campos and Guimarães, 2008; Wolf et al.,
2010). Moreover, the analysis of endocannabinoid signaling
elements and related proteins in lymphocytes of patients
with Dravet syndrome showed changes in the alpha-1H
unit of the voltage-dependent calcium channel and an up-
regulation of CB2 receptors, associated with an activation
of lymphocytes and changes in inflammation-related genes
(Rubio et al., 2016). These changes have been described
in inflammatory diseases and epilepsy and may support
a potential dysregulation of the endocannabinoid system
in the SNC.
We cannot exclude the possibility that the case presentations
may have been impacted by the side effects and pharmacokinetic
interactions of the other medications the children were taking,
or even by other chemical substances that could be present
in the cannabis extracts initially used. However, neither
the cannabinoids nor the other medications are known to
induce mydriasis or eye redness and the patients presented
improvements with CBD.
The two cases reported here highlight the need for cannabis-
derived compounds produced according to good laboratory
and manufacturing practices (GMP/GLP) that could lead
to the development of medicines consistently produced and
controlled by international regulatory standards. The use
of handcrafted, uncontrolled cannabis-based medicines by
children and adolescents raises special concerns because of
the well-known harmful long-term effects of 19-THC on the
developing brain (Volkow et al., 2014). The potentially toxic
effects of 19-THC and other cannabis constituents, including
cognitive impairment and chronic psychiatric disturbances,
have not yet been well studied in younger patients who
might be more vulnerable than adults to potential long-term
adverse effects (Volkow et al., 2014). Therefore, randomized
clinical trials using high-quality and reliable cannabis-derived
substances without other impurities (e.g., solvents) are required
to ascertain the safety and efficacy of cannabinoids as
medicines.
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